Pembrolizumab for Orbital and Periocular Cutaneous Squamous Cell Carcinoma (cSCC)
University of Michigan Rogel Cancer Center
Summary
This phase II trial studies how well pembrolizumab works in treating patients with orbital (eye socket) and/or periorbital (surrounding the eye socket) cutaneous squamous cell cancer (cSCC) that has spread to nearby tissue or lymph nodes (locally advanced) or has come back after a period of improvement (recurrent). Skin cancers that are close to the eye or on the eyelid often have more genetic (heredity) changes than other types of cancers. This means that the deoxyribonucleic acid (DNA) (the building blocks of the body that determine such things as the color of the hair) in tumor tissue has been altered compared to normal tissue. It is thought cancer cells with these DNA changes are more likely to respond to a type of drug called immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pembrolizumab is approved for patients with recurrent or metastatic cSCC not amenable (responsive) to cure by surgery or radiation. Giving pembrolizumab may work better in treating patients with locally advanced or recurrent orbital and/or periorbital cSCC.
Description
PRIMARY OBJECTIVE: I. To determine whether treatment of patients with locally advanced or recurrent orbital and/or periocular cSCC with pembrolizumab will be associated with tumor response. SECONDARY OBJECTIVES: I. To assess the globe preservation rate among patients with locally advanced or recurrent orbital and/or periocular cSCC treated with pembrolizumab. II. To determine whether treatment with pembrolizumab of patients with locally advanced or recurrent orbital and/or periocular cSCC will prevent progression of disease. EXPLORATORY OBJECTIVES: I. To evaluate next generation sequenci…